Doseology Receives Management Cease Trade Order for Late Annual Filings, Targets November 15

Doseology Sciences Inc. received a management cease trade order after failing to file its annual audited financial statements for the year ended June 30, 2026 by the October 28, 2026 deadline. Stock Titan reported the order permits continued share trading by persons other than company insiders and employees while the annual filings remain overdue. Doseology is a Kelowna, British Columbia-based consumer health company selling functional mushroom supplements and caffeine-based oral stimulant pouches under the Feed That Brain brand.

Doseology's Filing Delay and Auditor Timeline

The company said the delay is not the result of any unresolved accounting matters, outstanding information requests, or delays by management. Doseology said its auditor will need approximately two additional weeks to complete the audit of its annual financial statements. The company applied for and received the management cease trade order under National Policy 12-203 to permit continued trading in its common shares by persons other than insiders and employees. Doseology said its staff is working with its auditors and anticipates filing the annual audited financial statements, management's discussion and analysis and related certifications on or before November 15, 2026. The company confirmed it will comply with the alternative information guidelines in NP 12-203 and will issue bi-weekly default status reports for as long as it remains in default. Aktien also reported the two-week audit estimate, the November 15, 2026 filing target and the bi-weekly default status reports.

Doseology's OTCQB Listing and Feed That Brain Launch

According to akta.pro company records, Doseology's common shares commenced trading on the OTCQB Venture Market in the United States under the symbol DOSEF in March 2026. The same records show the company launched Feed That Brain Energy Pouches in the U.S. through a direct-to-consumer pilot at feedthatbrain.com and Amazon.com in March 2026, marking the first commercial deployment of its oral stimulant platform. In January 2026, Doseology engaged McKinney Regulatory Science Advisors as a strategic regulatory partner to lead FDA submission strategy, PMTA preparation and post-market compliance for its oral pouch products.

Doseology's Director Resignation and Private Placement

On October 14, 2026, Doseology announced that Larry Latowsky resigned as a director, effective immediately, without disclosing a reason, Aktien reported. In June 2026, Doseology extended the closing of its non-brokered private placement by 45 days, Newswire reported; the offering will sell up to 3,225,806 units at $0.62 each, raising up to $2 million, with proceeds to fund commercialization of oral pouch products. In May 2026, the company extended the same placement's closing by 45 days and announced Tim Corkum's resignation as President and COO, Newswire reported.

Doseology's November 15 Filing Target

Doseology anticipates filing its annual audited financial statements, management's discussion and analysis and related certifications on or before November 15, 2026, and will issue bi-weekly default status reports while it remains in default.